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Abstract
Background: Intense interest surrounds the recent expansion of US National Institutes of Health (NIH) budgets as part of
economic stimulus legislation. However, the relationship between NIH funding and cardiovascular disease research is poorly
understood, making the likely impact of this policy change unclear.
Methods: The National Library of Medicine’s PubMed database was searched for articles published from 1996 to 2006,
originating from U.S. institutions, and containing the phrases ‘‘cardiolog,’’ ‘‘cardiovascular,’’ or ‘‘cardiac,’’ in the first author’s
department. Research methodology, journal of publication, journal impact factor, and receipt of NIH funding were recorded.
Differences in means and trends were tested with t-tests and linear regression, respectively, with P#0.05 for significance.
Results: Of 117,643 world cardiovascular articles, 36,684 (31.2%) originated from the U.S., of which 10,293 (28.1%) received
NIH funding. The NIH funded 40.1% of U.S. basic science articles, 20.3% of overall clinical trials, 18.1% of randomized-
controlled, and 12.2% of multicenter clinical trials. NIH-funded and total articles grew significantly (65 articles/year, P,0.001
and 218 articles/year, P,0.001, respectively). The proportion of articles receiving NIH funding was stable, but grew
significantly for basic science and clinical trials (0.87%/year, P,0.001 and 0.67%/year, P=0.029, respectively). NIH-funded
articles had greater journal impact factors than non NIH-funded articles (5.76 vs. 3.71, P,0.001).
Conclusions: NIH influence on U.S. cardiovascular research expanded in the past decade, during the period of NIH budget
doubling. A substantial fraction of research is now directly funded and thus likely sensitive to budget fluctuations,
particularly in basic science research. NIH funding predicts greater journal impact.
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Introduction
In a speech given at the 2006 American Heart Association
national meeting, Dr. Elias A. Zerhouni, Director of the National
Institutes of Health (NIH), emphasized the tremendous benefit
derived from prior government funding of clinical research. Dr.
Zerhouni used coronary artery disease as an example, where
research has prevented one million early deaths at a cost of
supporting the NIH of $3.70 per American per year. Despite these
proven benefits, the likelihood of an investigator obtaining NIH
research funding dropped by a third from 2003 to 2006 [1]. From
2003 to 2008, NIH budgets stagnated, and even declined in terms
of real purchasing power [2,3]. Dr. Zerhouni described the
situation as a ‘‘perfect storm,’’ and was ‘‘deeply troubled’’ about
the impact on investigators, particularly junior scientists beginning
a career [4]. In February 2009, the issue of NIH funding again
took center stage with the passage of the American Recovery and
Reinvestment Act (ARRA), which promised an additional $10.4
billion to be spent by fiscal year 2010, a substantial boost for the
$30.3 billion 2009 NIH budget [3,5].
Adequate funding is critical for continued advancement in
cardiovascular disease research. In 2008, the NIH budget was
approximately $29 billion, with about $2.9 billion directed toward
the National Heart, Lung, and Blood Institute (NHLBI), the
institute most directly involved with cardiovascular research [6].
Despite these well-publicized budgetary figures, the actual impact
of the NIH on published cardiovascular research is poorly
understood. Money flows from the government to research
institutions, but the return on that investment, in terms of the
quality and quantity of research publications, is almost entirely
unknown.
Quantifying the output of U.S. cardiovascular research, both
NIH-funded and unfunded, is important. Doing so provides a
baseline understanding of the volume and characteristics of
cardiovascular research, and also allows trend analysis to
determine if research productivity is increasing, decreasing, or
stagnant. The relative proportion of NIH-funded to total research
is also of importance. A large proportion of NIH-funded papers
suggests a heavy dependence on direct NIH support. In this
instance, research output may change dramatically in response to
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research productivity is less influenced by the NIH. In the current
context of a surge in available research funding secondary to the
ARRA, this information has important policy implications and
could impact decisions on grant appropriations. For overall U.S.
biomedical research, the NIH accounts for 24% to 28% of total
research funding [7]. Specialty-specific studies examining the role
of the NIH in research have been performed in radiology [8,9],
emergency medicine [10,11], otolaryngology [12], and neurology
[13]. For cardiovascular disease however, the publication impact
of NIH funding is unknown.
The purpose of this study was to determine the overall volume
of world and U.S. cardiovascular research articles, and the
component of U.S. cardiovascular articles that did and did not
receive NIH funding during the eleven years from 1996 to 2006.
NIH funding levels were examined overall and by research
methodology to determine which methodologies were most likely
to receive funding. Trends were analyzed to determine if funding
impact changed over time. The average journal impact factor was
examined to determine if article methodology or receipt of NIH
funding was associated with the likely scientific impact of the
article. Finally, the contributions of individual NIH institutes were
examined to determine which ones had budgets and agendas that
were most supportive of cardiovascular research. These results
provide an overview of the NIH funding landscape in cardiovas-
cular disease research and provide important information for
policymakers, research leaders, and clinical investigators who are
involved with research grants, and for practicing clinicians
interested in continued benefits provided by research.
Methods
Source of Data
This study is a retrospective observational study of publicly
available data, and was exempted from Institutional Review Board
approval. Data collection was performed by MWI, and analysis
and interpretation was performed by MWI, RL, and BKI. The
data were obtained from PubMed, a freely available database of
biomedical citations and abstracts hosted by the National Library
of Medicine. The largest component of PubMed is MEDLINE, a
database that contains information from more than 5,200
biomedical journals published in more than 80 countries, and in
37 languages [14,15]. PubMed contains over 18.8 million citations
[16].
Data selection
All articles published during the 11-year period from January 1,
1996 to December 31, 2006 that were indexed in PubMed as of
June 20, 2007 and contained the words ‘‘cardiac,’’ ‘‘cardiovascu-
lar,’’ and ‘‘cardiolog’’ in the first author affiliation field were
captured. The author affiliation field is a PubMed defined field
that contains the first author’s department, institution, and
country. This method allowed capture of citations published by
departments of cardiology and related specialties, including
surgical, pediatric, and basic science disciplines. In instances
where an author was not from a cardiovascular related
department but worked within a larger institution dedicated to
cardiovascular research, the paper was included. Papers from
veterinary medicine departments were specifically excluded as
they typically deal with research unrelated to humans. The
selection was thus conservative in nature, tending to exclude some
legitimate articles where the first author is from an unrelated
department in order to ensure that the included articles had the
highest chance of being truly cardiovascular in nature. The goal of
the chosen keyword selection algorithm was thus not to capture all
cardiovascular articles, but rather to capture a large subset with
maximum accuracy.
The matching citation data were reconstructed in a dedicated
research database. For each article, the original PubMed-defined
fields were preserved, including the author affiliation, year,
volume, issue, journal of publication, article methodology, and
NIH supporting institute, if any. Each article had one or more
methodology types as defined by the National Library of
Medicine: case reports, which describe clinical presentations;
review articles, which examine published material on a subject;
multicenter studies, which describe a controlled study performed
at multiple institutions; therapeutic comparison studies, which
compare therapeutic techniques and approaches; process evalua-
tions, which examine the utility and effectiveness of processes;
process validations, which study the reliability of processes; In vitro
studies, which examine excised tissue; clinical trials (of any type),
which describe pre-planned clinical studies typically involving
humans, or controlled, randomized-controlled, Phase I, II, III, or
IV clinical trials. Precise definitions of these publication method-
ologies are available from the National Library of Medicine [17].
Two additional methodological types were created: Research
articles with no specified subtype comprise a large fraction of the
published literature and typically consist of basic science
laboratory or early clinical research. These articles were labeled
‘‘unspecified, general research.’’ Multicenter studies that were also
clinical trials were given the label ‘‘multicenter clinical trial.’’ If the
article acknowledged receipt of NIH grant support, the sponsoring
NIH institute was noted. While PubMed has standardized
indexing of NIH grants, no standardized method of indexing
non-NIH funding exists. Thus, only NIH grants were captured. In
cases where articles had support from two or more NIH agencies,
each agency was given equal credit for the publication. Country
assignment was based on automated detection of the country, city,
or institution in the first author’s affiliation field.
Journal impact factor (JIF) values of the publishing journal were
obtained from Thompson Scientific Journal Citation Reports and
assigned to each article by the year and journal of publication [18].
A journal’s impact factor is calculated as the total number of
citations in a year referencing articles from a journal’s prior two
years, divided by the number of articles from a journal’s prior two
years [19]. While not a perfect measure of an article’s scientific
significance, JIF has been found to be associated with article
methodological strength and subsequent scientific impact [20,21].
JIF values were assigned to individual articles using journal titles
and ISSN numbers. Data were available for 7467 unique journals
from 1997 to 2006. Mean JIF values for NIH-funded, non-NIH-
funded, and total U.S. articles were calculated. Calculations were
also performed for each article methodology. Articles without
assignable JIF values were excluded from the calculations.
To quantify the accuracy of the selection criteria, randomly
generated 500 citation data sets were compared to human review
as a gold standard. Manual review was performed by RL.
Detected errors were confirmed by consensus of the authors. In a
set of articles identified as U.S. cardiovascular, 497 of 500 (99.4%)
were properly classified as originating from cardiovascular or
related departments or institutions, and 497 of 500 (99.4%) were
properly identified as originating from the United States. In a set
of worldwide articles, 500 of 500 (100%) were properly classified as
originating from cardiovascular or related departments or
institutions, and 479 of 500 (95.8%) had been assigned to the
correct country of origin. Inability to assign country occurred
primarily when incomplete information regarding the author’s
institution was provided.
The NIH in Cardiac Research
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Statistical analysis was performed using SPSS software (Win-
dows version 11.5, SPSS, Inc. Chicago, IL, USA). Ordinary least
squares regression analysis was used to test for trend, that is, a
nonzero slope over the 11-year study period. Two tailed t-tests
were used to test for differences in mean journal impact factor
values. A P-value of less than or equal to 0.05 was used as a
threshold for significance.
Results
A total of 117,643 cardiovascular disease journal articles published
between the years 1996 to 2006 were identified from 2,982 unique
journals. Of those, 36,684 articles from 1,788 journals originated
from the United States and comprised the final data set. U.S.
institutions published approximately one-third (31.2%) of the world
total. U.S contributions met or exceeded 35% of the world total for
meta-analyses, in vitro studies, process validations, multicenter
studies, multicenter trials, and phase II trials. U.S. contributions
exceeded 40% for review articles, phase I, and phase IV trials, and
exceeded 50% for phase III trials. Less than one-quarter of the
world’s case reports, controlled, randomized-controlled, and overall
clinical trials originated from the U.S., Table 1.
Significant growth was seen for overall U.S. cardiovascular
publications over the 11-year study period, with publications
increasing an average 218 articles per year (P,0.001). Significant
growth was seen for all methodological subtypes except in vitro studies
and phase-type trials, and was particularly great for review articles
(72.8 articles/year), Table 2. Process evaluation and validation studies
were excluded from trend analysis because PubMed did not
consistently index these publication types prior to 2001.
NIH-funded U.S. articles numbered 10,293 (28.1% of all U.S.
articles). The NIH contributed heavily to general research (40.1%),
and relatively less to clinical trials of any type (20.3%) and
multicenter studies (17.6%). Support levels were particularly low for
multicenter trials (12.2%), Phase II trials (11.1%), and Phase III and
IV trials (both 0%), Table 1. NIH-funded articles grew by 64.6
articles per year (P,0.001). Significant growth was seen for NIH-
funded general research articles, review articles, therapeutic
comparisons, multicenter studies, and controlled, randomized-
controlled, multicenter, and overall clinical trials, Table 2. No
significant growth was detected for phase-type clinical trials.
While numbers of both total and overall NIH-funded U.S.
publications increased, there was no change in the relative
proportion of NIH-funded articles. Statistically significant growth
in this proportion was detected for a few specific methodologies,
namely general research articles (0.87% per year, P=0.005),
therapeutic comparisons (0.52% per year, P=0.017), randomized-
controlled trials (0.92% per year, P=0.007), and overall clinical
trials (0.67% per year, P=0.029). For these methodologies, the
relative impact of the NIH expanded. Support for meta-analyses
decreased (4.47% per year, P=0.021), and all other methodologies
showed no significant change, Table 2. Comparative growth in
selected article methodologies is depicted in Figure 1.
The mean journal impact factor of U.S. cardiovascular journal
articleswas4.38,andwasnotablygreaterforrigorousmethodologies
such as multicenter trials (6.13), multicenter studies (5.74),
randomized-controlled trials (5.43), and overall clinical trials (5.01).
Table 1. Worldwide, U.S., and U.S. NIH-funded cardiovascular research articles, 1996–2006, by article study characteristics and
methodology.
Study characteristics and methodology Worldwide U.S. (% of world) U.S. NIH-funded (% of U.S.)
Case reports 18,004 3,879 (21.5%) 65 (1.7%)
Review articles 18,570 7,844 (42.2%) 1,152 (14.7%)
Therapeutic comparisons 17,140 4,799 (28.0%) 1,168 (24.3%)
Process evaluations 2,685 738 (27.5%) 151 (20.5%)
Process validations 560 198 (35.4%) 57 (28.8%)
In vitro studies 2,604 937 (36.0%) 589 (62.9%)
Multicenter studies 2,682 948 (35.3%) 167 (17.6%)
Meta-analyses 370 135 (36.5%) 13 (9.6%)
Twin studies 26 0 (0.0%) 0 (0.0%)
Clinical trials, all types 10,508 2,396 (22.8%) 487 (20.3%)
Controlled clinical trials 1,216 235 (19.3%) 62 (26.4%)
Randomized controlled trials 5,889 1,403 (23.8%) 254 (18.1%)
Multicenter trials 1,622 622 (38.3%) 76 (12.2%)
Phase I trials 64 28 (43.8%) 6 (21.4%)
Phase II trials 103 36 (35.0%) 4 (11.1%)
Phase III trials 41 22 (53.7%) 0 (0.0%)
Phase IV trials 11 5 (45.5%) 0 (0.0%)
Unspecified, general research 53,157 17,078 (32.1%) 6,850 (40.1%)
Miscellaneous articles 1,233 656 (53.2%) 27 (4.1%)
All journal articles 117,643 36,684 (31.2%) 10,293 (28.1%)
Articles may belong to more than one category, thus the sum of the categories do not necessarily equal the total. Unspecified, general research are research articles with
no specified subtype. Miscellaneous articles are journal articles without scientific content, such as bibliographies, biographies, comments, letters, historical articles,
guidelines, editorials, news, indices, legal cases, interviews, and consensus statements. Additional information on publication characteristics and methodologies is
available at the National Library of Medicine website, at http://www.nlm.nih.gov/mesh/pubtypes2008.html.
doi:10.1371/journal.pone.0006425.t001
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(3.81) had the lowest impact factors. NIH-funded and non-NIH-
funded articles had different mean journal impact factors in certain
instances, as depicted in Figure 2. Impact factors were significantly
greater for NIH-funded general research articles, case reports,
review articles, in vitro studies, process evaluations, therapeutic
comparisons, controlled clinical trials, and overall journal articles.
The leading NIH supporter of U.S cardiovascular publications
was the National Heart, Lung and Blood Institute (NHLBI), which
sponsored 8,898 publications, or 86.4% of all NIH-funded articles.
Other major NIH supporters included the National Center for
Research Resources (NCRR, 825 articles, 8.0%), the National
Institute of Diabetes, & Digestive & Kidney Diseases (NIDDK,
680 articles, 6.6%), and the National Institute on Aging (NIA, 679
articles, 6.6%). The NHLBI demonstrated the greatest growth in
publications, funding an additional 53.1 articles annually
(P,0.001), followed by the NIA (10.5 articles/year, P,0.001)
and NCRR (10.5 articles/year, P,0.001). A total of 12 NIH
institutes exhibited significant growth in sponsored articles,
Table 3. Of particular note was the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), the NIH
institute most directly responsible for funding imaging and
bioengineering research. Founded in December 2000, the 11-
year trend analysis applied to other institutes is less appropriate for
the NIBIB [22]. When a six-year analysis was performed on the six
complete years of its existence, 2001 to 2006, the NIBIB exhibited
an annual growth of 7.7 articles/year (P=0.003), the fifth greatest
growth rate among NIH institutes.
Discussion
The United States made a significant contribution to the world
cardiovascular research literature, publishing slightly less than one
third of all cardiovascular research articles over the study period.
American investigators had a relative focus on expensive, high
methodological strength trials, such as multicenter and phase-type
trials. They accounted for more than one-third of the worldwide
output of these trials, and in the case of Phase III trials, more than
half. Perhaps as a result of the expertise and renown gained by this
high profile research, U.S. investigators also published a
disproportionately large and growing number of review articles.
The bulk of worldwide clinical trials are of the non-multicenter
variety, such as single center controlled or randomized-controlled
clinical trials. The U.S. contributed less than a quarter of the world
output of these trial types. Additionally, relatively few of the most
inexpensive article type, case reports, originated from the U.S.
Despite the U.S. strength in large clinical trials, the NIH was
less involved in sponsoring this type of research. While 28% of
overall U.S. cardiovascular articles were NIH-funded, only 20.3%
of clinical trials and 12.2% of multicenter trials received NIH
sponsorship. The prohibitive cost of these trials may have been left
to parties with the wealth and incentive to support them, namely
industry. While this study did not directly investigate industrial
sources of funding due to unstandardized reporting of industrial
research support, it seems reasonable to assume that industry
accounts for a large component of this funding gap, especially
since in the general biomedical literature industrial support is twice
that of the NIH [7]. Large clinical trials most directly and
immediately impact clinical practice. Significant industry financing
can improve and accelerate existing research and support ideas
that might not otherwise be funded. On the other hand, conflict of
interest and bias are important considerations when the sponsor-
ing party has a financial interest in the research results [23,24].
NIH support of clinical trials did exhibit significant growth, both
in terms of absolute publications and relative proportion to total
U.S. clinical trials. This growth coincided with the expansion of
NIH and NHLBI budgets, the former of which more than doubled
between 1998 and 2003 [5,6]. Given the time lag between grant
receipt and publication of final results for clinical trials, typically
several years, it is possible that the NIH budget doubling was not
fully expressed in the publications of this study period. If this is the
case, then the period of budget stagnation from 2004 to 2008 was
probably also not expressed. The full impact of NIH budget
Table 2. Annual growth in total U.S., U.S. NIH-funded, and relative NIH-funded cardiovascular research articles, 1996–2006.
Methodology All articles NIH-funded articles Relative proportion (NIH-funded/All)
Annual growth rate P-value Annual growth rate P-value Annual growth rate P-value
Articles % of 1996 Articles % of 1996 D ratio % of 1996
Case reports 31.7 12.9% ,0.001 0.31 5.2% 0.187 0.000 0.0% 0.557
Review articles 72.8 18.5% ,0.001 13.11 20.2% ,0.001 0.003 1.8% 0.076
Therapeutic comparisons 34.0 12.1% 0.001 10.64 15.6% ,0.001 0.005 2.1% 0.017
In vitro studies 20.9 21.4% 0.697 0.10 0.3% 0.954 0.010 1.9% 0.099
Meta-analyses 2.2 36.7% ,0.001 20.12 -12.0% 0.224 -0.045 -27.0% 0.021
Multicenter studies 9.1 17.5% ,0.001 2.08 23.1% ,0.001 0.006 3.5% 0.092
Clinical trials, all types 15.4 12.3% ,0.001 4.44 17.1% ,0.001 0.007 3.4% 0.029
Controlled trials 2.8 31.1% 0.001 0.74 24.7% ,0.001 -0.002 20.6% 0.842
Randomized-controlled trials 9.0 11.1% ,0.001 2.72 18.1% ,0.001 0.009 4.9% 0.007
Multicenter trials 4.4 11.3% ,0.001 0.72 9.0% 0.006 0.002 1.0% 0.597
Unspecified, general research 51.2 4.2% 0.003 32.71 8.1% ,0.001 0.009 2.7% 0.005
All journal articles 218.2 9.7% ,0.001 64.55 11.0% ,0.001 0.002 0.8% 0.345
All U.S. and NIH-funded U.S. growth rates are expressed in terms of articles per year, with relative growth expressed as a percentage of the 1996 level. The proportional
growth in NIH-funded articles is expressed as the annual change in the ratio of NIH-funded to all articles, e.g. growth from 30% NIH-funded in 1996 to 41% NIH-funded
in 2006 corresponds to a yearly growth of approximately 0.01, or 1 percent per year. Figures normalized to 1996 for this proportion are also depicted. Insufficient
numbers of phase-type clinical trials were published to allow meaningful analysis of trend for these methodologies.
doi:10.1371/journal.pone.0006425.t002
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remains to be seen. Since the overall trend is for clinical trials to be
more dependent on NIH funding over time, the funding boost
from the ARRA may have more beneficial impact than would
otherwise be expected, especially if specific efforts are made to
fund clinical trials with ARRA funds.
While NIH support of clinical trials is relatively limited, the
converse is true for general research articles, 40.1% of which
received NIH support. This proportion is far larger than any other
article type. The basic science questions these articles typically
examine may not yet be commercially viable. In this instance, the
NIH may be filling a need for funding of discovery research that
has no immediate commercial application, and is thus of lesser
priority for corporate sponsors–a well-justified reason for govern-
ment support [25]. Over the study period, overall general research
articles grew significantly, but NIH-funded general research
articles grew at a proportionally greater rate. Thus, the component
of U.S. basic science and early clinical cardiovascular disease
research that was directly funded by the NIH increased. These
findings imply that fluctuation in NIH funding levels may have a
disproportionately large impact on basic science research. Since
basic science research precedes clinical research and ultimately
clinical adoption, future clinical advances may be significantly
compromised by the period of budget stagnation from 2003 to
2008, and significantly enhanced by the recent ARRA legislation.
The overall impact of NIH funding on publications grew
steadily during the study period both overall and for many
methodological types. The total number of NIH-funded articles
more than doubled during the 11-year study period, increasing at
64.6 additional articles per year. The only methodologies that did
not show growth in NIH-funded publications were meta-analyses,
case reports, in vitro studies, and phase-type trials. During this
same period, overall U.S. cardiovascular publication output grew
by 218 articles per year, with significant growth seen for every
methodological subtype except in vitro studies, the most rapidly
growing of which was curiously review articles. Their growth may
represent a growing need for articles to decipher and clarify an
increasingly complex medical literature.
This growth in NIH-funded publications matched the growth in
overall U.S. cardiovascular publications. The ratio of NIH-funded
to overall U.S. articles, an indicator of relative growth, was
essentially stable over the study period. Nominal but statistically
significant increases in this proportion were detected for general
research articles, randomized-controlled trials, and clinical trials of
Figure 1. Trends in NIH-funded and overall U.S. cardiovascular disease articles, 1996–2006, selected methodologies. Data were
normalized to 1996 levels. All article types depicted here had statistically significant growth except all U.S. general research articles. Furthermore the
ratio of NIH-funded to overall articles increased significantly for general research articles and clinical trials, indicating a proportionally increasing role
played by the NIH for these article types.
doi:10.1371/journal.pone.0006425.g001
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same period of time, the budget of the NHLBI grew from $1.35
billion in 1996 to $2.94 billion in 2005 [6]. This 217% increase in
funding was matched by a doubling of NIH-funded articles over
the same period. This growth was just enough to keep the NIH-
funded component of all U.S. cardiovascular research stable at
about 28%.
The impact factor of a publishing journal is predictive of the
subsequent dissemination and likely scientific impact of its articles
[21]. NIH-funded papers had greater journal impact factors than
their non-NIH-funded cohorts, both overall and for numerous
methodological subtypes, suggesting that these articles had a
greater dissemination and scientific impact when compared with
other similar articles. The reason for this difference is unknown.
One possible explanation is that the NIH effect is directly
causative, that is, the additional resources and prestige that come
with NIH support improve the quality or perceived quality of the
research, enabling publication in more prestigious journals.
Another possibility is a correlative relationship. For instance, the
intense scrutiny of the grant application process may select for
more talented investigators who subsequently produce better
research and publish in more prestigious journals on their merit
alone. Alternatively, a combination of effects may be at play.
While predictive of greater journal impact for other article types,
NIH-funding did not predict a statistically significant difference in
journal impact for any clinical trial type except controlled clinical
trials. This finding again supports the notion that the NIH is not
unduly influential in clinical trials, where NIH sponsorship is
relatively low. In some instances, such as with Phase I and II trials,
the small number of NIH-funded studies made detection of all but
the largest differences difficult.
The NHLBI was by far the dominant NIH institute providing
funding for cardiovascular research. It was involved in more than
6 out of 7 NIH-sponsored cardiovascular publications and
exhibited the greatest rate of support growth. The NIA and
NIDDK also exhibited strong historical support and growth, an
Figure 2. Mean journal impact factor of NIH-funded and non-NIH-funded U.S. cardiovascular disease articles, 1997 to 2006, by
article methodology. P-values denote the difference between NIH-funded and non NIH-funded journal impact factors when means were
compared with two-tailed t-tests. There was insufficient data for comparisons of Phase III and Phase IV clinical trials.
doi:10.1371/journal.pone.0006425.g002
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aging, and heart disease. Of interest is the relatively rapid growth
in support from the NIBIB, the institute most directly responsible
for imaging and bioengineering research. Founded in December,
2000, and the youngest of the NIH institutes, the NIBIB is strongly
associated with clinical research in radiology [22]. The fact that its
growth in cardiovascular disease research is so prominent, suggests
that cardiac imaging may be an important funding priority.
Cardiovascular disease investigators working with imaging should
consider the NIBIB as a potential source of grant support.
Study Limitations
There are several limitations of this study that are important to
consider. First, data analyzed were limited to publications indexed
in the National Library of Medicine’s PubMed database. PubMed
indexes about 5,200 journals published in 80 countries, and
contains more than 18.8 million citations [14,16]. While very
comprehensive, PubMed is not perfect, and any bias in journal
inclusion or accuracy of data field indexing could impact the study
results. Generally however, PubMed is widely considered to be an
accurate and reliable resource. Another consideration is the use of
the first author’s affiliation to assign the country and department of
origin. Articles pertaining to cardiovascular disease in which the
first author is not from a cardiovascular or related department
would not have been counted. Furthermore, articles where the first
author is from a cardiovascular department but is writing about an
unrelated topic would be erroneously included. On the other
hand, giving equal credit to all authors in multiauthor papers runs
the risk of overestimating the contribution of non-first authors.
Several studies have shown that first authors make the most
substantial contributions to the published work, and are the
authors most deserving of credit [26,27]. Journal impact factor,
while indicative of a journal’s prestige and likely scientific impact
of its articles in aggregate, is not necessarily indicative of an
individual article’s scientific impact. This should be kept in mind
when interpreting JIF results. Finally, the paper makes no attempt
to account for variation in the competitiveness of NIH funding in
different study years.
Conclusions
In summary, this study provides a comprehensive overview of
the impact of NIH funding on published U.S. cardiovascular
disease research. By including 36,684 U.S. cardiovascular disease
articles published during the 11-year study period, the data set was
very comprehensive. The U.S. accounted for about one third of
worldwide publications on cardiovascular disease, with a relative
emphasis on large clinical trials and review articles. The NIH
funded 28% of U.S. articles, with an emphasis on basic science
research. Most large U.S. clinical trials received alternative
funding, likely from industrial sources. NIH-funded articles of
several methodologies were more likely to be published in high
impact journals. Both overall U.S. cardiovascular publications and
NIH-funded publications increased, but at roughly equivalent
rates such that the ratio between the two was stable. The NHLBI
was by far the dominant institute funding cardiovascular research,
but growth from the NIBIB was unexpectedly strong, suggesting a
growing federal interest in cardiac imaging.
Table 3. Sponsored articles in cardiovascular disease research from individual NIH institutes, 1996–2006, with 11-year annualized
growth rates.
NIH Institute Abbrev. Funded articles (%) Growth (articles/yr) P-value 95% CI
National Heart, Lung, and Blood Institute NHLBI 8,898 (86.4%) 53.1 ,0.001 (37.3–68.8)
National Center for Research Resources NCRR 825 (8.0%) 10.5 ,0.001 (8.1–12.9)
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK 680 (6.6%) 7.8 ,0.001 (6.4–9.2)
National Institute on Aging NIA 679 (6.6%) 10.5 ,0.001 (7.8–13.3)
National Cancer Institute NCI 459 (4.5%) 5.2 ,0.001 (3.3–7.0)
National Institute of General Medical Sciences NIGMS 416 (4.0%) 3.2 ,0.001 (1.7–4.6)
National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS 255 (2.5%) 1.9 0.001 (1.0–2.8)
National Institute of Neurological Disorders and Stroke NINDS 244 (2.4%) 0.9 0.151 (20.4–2.2)
National Institute of Child Health and Human Development NICHD 229 (2.2%) 2.3 0.004 (0.9–3.7)
National Institute of Allergy and Infectious Diseases NIAID 183 (1.8%) 1.6 ,0.001 (0.9–2.4)
National Institute of Biomedical Imaging and Bioengineering* NIBIB 109 (1.1%) 7.7 0.003 (4.3–11.2)
National Eye Institute NEI 91 (0.9%) 1.8 0.001 (0.9–2.6)
National Institute of Environmental Health Sciences NIEHS 81 (0.8%) 0.7 0.062 (0.0–1.3)
National Institute on Drug Abuse NIDA 49 (0.5%) 0.3 0.284 (20.3–0.8)
National Institute of Mental Health NIMH 47 (0.5%) 0.2 0.161 (20.1–0.6)
National Institute on Alcohol Abuse and Alcoholism NIAAA 44 (0.4%) 0.4 0.15 (20.2–0.9)
John E. Fogarty International Center FIC 25 (0.2%) 20.4 0.024 (20.7–20.1)
National Institute of Nursing Research NINR 21 (0.2%) 0.2 0.123 (20.1–0.4)
National Institute on Deafness and Other Communication Disorders NIDCD 19 (0.2%) 0.4 0.045 (0.0–0.9)
National Institute of Dental and Craniofacial Research NIDCR 17 (0.2%) 0.2 0.306 (20.2–0.5)
Individual articles may have received support from more than one institute, thus the sum of the percentiles from each institute exceeds 100%.
*The National Institute of Biomedical Imaging and Bioengineering (NIBIB) was created in December 2000, and thus no data were available for the first 5 years of the
study. Trend analysis was performed on the 6 years for which data were available, 2001 to 2006.
doi:10.1371/journal.pone.0006425.t003
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